Contribute Try STAT+ Today

Next week, the Food and Drug Administration is expected to approve a new medicine from Aurinia Pharmaceuticals that will be used to treat patients with lupus nephritis, a serious autoimmune kidney disease.

If the decision goes Aurinia’s way, the oral drug called voclosporin will be the first commercial product developed successfully by the drug maker, founded in 1993 and based in Victoria, British Columbia, in Canada.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Important to note voclosporin would be the only oral drug in this segment, a huge advantage vs IV MABs

  • Fun fact: Aurinia was originally founded as a company called Isotechnika and was only renamed Aurinia when the team behind Aspreva took over the company in 2013 to reposition voclosporin for patients with LN, hence the relatively short original patent life. To that end, I think the 1993 founding date is a bit of a misnomer, as the current incarnation of the company launched about seven years ago.

Comments are closed.